Canagliflozin Targeting Vascular Inflammation

NCT05427084 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Type 2
Coronary Artery Disease

Interventions

DRUG: Canagliflozin
DRUG: Placebo

Sponsor

Ottawa Heart Institute Research Corporation